Zydus Lifesciences Limited (NSE:ZYDUSLIFE) disclosed on 21 August 2026 that it has received final approval from the United States Food and Drug Administration for its ANDA for Ascorbic Acid Injection USP, carrying a 180-day Competitive Generic Therapy exclusivity designation.
Key Highlights
- The USFDA granted final ANDA approval for Ascorbic Acid Injection USP in two presentations: 25,000 mg/50 mL (500 mg/mL) and 5,000 mg/10 mL (500 mg/mL).
- The ANDA holds a Competitive Generic Therapy designation, making Zydus eligible for 180-day CGT exclusivity running from the first day of commercial marketing.
- The reference listed drug, Ascor Injection, recorded annual US sales of approximately USD 11.6 million per IQVIA MAT June 2026 data.
- The product will be manufactured at Zydus' USFDA-approved injectable plant at Jarod, near Vadodara, Gujarat, and marketed in the US by Zydus Pharmaceuticals (USA) Inc.
About the Company
Zydus Lifesciences Limited (NSE:ZYDUSLIFE), headquartered in Ahmedabad, Gujarat, is a vertically integrated pharmaceutical company that develops and manufactures generics, biosimilars, consumer wellness products, and new chemical entities. The company operates across the US, India, emerging markets, and Europe, with multiple USFDA-inspected manufacturing facilities covering oral solids, injectables, and biologics.
Announcement in Detail
The USFDA approval covers Ascorbic Acid Injection USP in two strengths: 25,000 mg/50 mL (500 mg/mL) and 5,000 mg/10 mL (500 mg/mL). The product is indicated for the short-term treatment of scurvy in adult and paediatric patients aged five months and older for whom oral administration is not possible, insufficient, or contraindicated. It is the generic equivalent of the reference listed drug Ascor Injection 25,000 mg/50 mL (500 mg/mL).
The USFDA designated the ANDA as a Competitive Generic Therapy. The 180-day CGT exclusivity period, where applicable, commences from the first day of commercial marketing of the product by Zydus. Manufacturing will take place at the group's USFDA-approved injectable facility located at Jarod, near Vadodara in Gujarat. The product will be commercialised in the United States through Zydus Pharmaceuticals (USA) Inc., the group's US marketing subsidiary. As of 30 June 2026, Zydus holds 448 cumulative USFDA approvals and has filed 513 ANDAs in total.
Impact on Investors
Investors will note that the 180-day CGT exclusivity period offers Zydus a defined window to market the product without direct generic competition, during which the brand's US market size was approximately USD 11.6 million annually as per IQVIA MAT June 2026. The disclosed terms indicate that the exclusivity clock starts only upon the first commercial sale, meaning the timeline for revenue recognition depends on Zydus' own launch readiness and supply chain.
The filing shows that the product adds to a growing injectable portfolio manufactured at the Jarod plant, which already holds USFDA approval. Shareholders will observe that Zydus has now accumulated 448 USFDA approvals from 513 ANDA filings, reflecting ongoing pipeline execution. The CGT exclusivity, while time-limited, represents a structural opportunity that is not present in standard generic launches and is therefore a distinct commercial feature of this specific filing.
Sector / Market Context
The Indian pharmaceutical industry is the third largest globally by volume, supplying approximately 30% of US generic medicines by volume, according to the Indian Pharmaceutical Alliance. USFDA approvals with CGT designations have become an increasingly pursued avenue for Indian generic manufacturers, as CGT status is available for products addressing markets with limited generic competition, offering a degree of first-mover advantage to the approved applicant during the exclusivity window. Injectable generics, in particular, have seen consistent demand growth in the US market, partly reflecting hospital formulary rationalisation and supply reliability requirements following disruptions in recent years.